Preliminary pharmacokinetics of a new anthelmintic agent, CDRI-81/470 in healthy subjects

  • Nagaraja N
  • Singh S
  • Paliwal J
 et al. 
  • 5

    Readers

    Mendeley users who have this article in their library.
  • 0

    Citations

    Citations of this article.

Abstract

Single dose pharmacokinetic study of CDRI-81/470, a new broad spectrum anthelmintic agent, was carried out in 12 healthy human subjects after a single 375-mg oral dose. The serum, saliva and urine samples were analyzed by HPLC. The compound attained peak serum levels of 15.1±4.6 μg/ml in 2.6±1.1 h and could be measured up to 5 days. Mean serum AUC was 195±69 μg per h/ml. The compound showed a mean apparent elimination half-life of 12.1±4.5 h while mean residence time (MRT) was found to be 11.1±1.7 h. Extent of urinary excretion of CDRI-81/470 (2.3±0.7%) was less than that of its decarboxylate metabolite (5.3±2.2%) up to 10 h post dose. In vivo protein binding in serum was 93.1±1.2% and remained constant over in vivo concentration range. The salivary levels of CDRI-81/470 were higher than the corresponding unbound serum levels. There was a significant correlation between serum and salivary levels of CDRI-81/470, with a mean ratio of saliva to unbound serum levels of 2.04±0.24, indicating the possibility of predicting serum concentrations of CDRI-81/470 from non-invasive salivary sampling technique. Copyright (C) 1998 Elsevier Science B.V.

Author-supplied keywords

  • Benzimidazole anthelmintic
  • CDRI-81/470
  • Clinical pharmacokinetics
  • Human
  • Oral
  • Single-dose

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free